Top Retinal Disease Therapeutics Companies

Skyquest Technology's expert advisors have carried out comprehensive research and identified these companies as industry leaders in the Retinal Disease Therapeutics Market. This Analysis is based on comprehensive primary and secondary research on the corporate strategies, financial and operational performance, product portfolio, market share and brand analysis of all the leading Retinal Disease Therapeutics industry players.

Retinal Disease Therapeutics Market Competitive Landscape

The global retinal disease therapeutics market is fragmented in nature. The prominent players operating in the market are constantly adopting various growth strategies to stay afloat in the market. Product launches, innovations, mergers, and acquisitions, collaborations and partnerships, and intensive R&D are some of the growth strategies that are adopted by these key players to thrive in the competitive market. For instance, in October 2018, the University of Florida Research Foundation and the University of Pennsylvania reached an agreement with Ophthotech Corporation (IVERIC bio) to develop and market an adeno-associated virus (AAV) gene therapy product for the treatment of Best Vitelliform Macular Dystrophy (BVMD). The key market players are also constantly focused on R&D to supply industries with the most efficient and cost-effective and customized solutions for students. For instance, in May 2019, the FDA approved REGENERON's Eylea (aflibercept) injectable to treat all phases of diabetic retinopathy, lowering the risk of blindness in patients.

Top Players in Retinal Disease Therapeutics Market

  • Regeneron Pharmaceuticals, Inc. (USA) 
  • Roche Holding AG (Switzerland) 
  • Novartis AG (Switzerland) 
  • Allergan (part of AbbVie) (USA) 
  • Bayer AG (Germany) 
  • Oculis (Switzerland) 
  • REGENXBIO Inc. (USA) 
  • Adverum Biotechnologies, Inc. (USA) 
  • Kodiak Sciences Inc. (USA) 
  • EyePoint Pharmaceuticals, Inc. (USA) 
  • Apellis Pharmaceuticals, Inc. (USA) 
  • Iveric Bio, Inc. (USA) (Acquired by Astellas) 
  • Annexon Biosciences (USA) 
  • Hemera Biosciences (USA) (Acquired by Roche) 
  • Gyroscope Therapeutics (UK) (Acquired by Novartis) 
  • Graybug Vision, Inc. (USA) 
  • Clearside Biomedical, Inc. (USA) 
  • Ocuphire Pharma, Inc. (USA) 
  • Lineage Cell Therapeutics, Inc. (USA) 
  • Ocugen, Inc. (USA)

Retinal Disease Therapeutics Market

REPORT OVERVIEW BUY NOW

REQUEST FOR SAMPLE

Want to customize this report? REQUEST FREE CUSTOMIZATION

FAQs

Retinal Disease Therapeutics Market size was valued at USD 12.57 Billion in 2023 and is poised to grow from USD 13.74 Billion in 2024 to USD 28.08 Billion by 2032, growing at a CAGR of 9.3% during the forecast period (2025-2032).

The global retinal disease therapeutics market is fragmented in nature. The prominent players operating in the market are constantly adopting various growth strategies to stay afloat in the market. Product launches, innovations, mergers, and acquisitions, collaborations and partnerships, and intensive R&D are some of the growth strategies that are adopted by these key players to thrive in the competitive market. For instance, in October 2018, the University of Florida Research Foundation and the University of Pennsylvania reached an agreement with Ophthotech Corporation (IVERIC bio) to develop and market an adeno-associated virus (AAV) gene therapy product for the treatment of Best Vitelliform Macular Dystrophy (BVMD). The key market players are also constantly focused on R&D to supply industries with the most efficient and cost-effective and customized solutions for students. For instance, in May 2019, the FDA approved REGENERON's Eylea (aflibercept) injectable to treat all phases of diabetic retinopathy, lowering the risk of blindness in patients. 'Regeneron Pharmaceuticals, Inc. (USA) ', 'Roche Holding AG (Switzerland) ', 'Novartis AG (Switzerland) ', 'Allergan (part of AbbVie) (USA) ', 'Bayer AG (Germany) ', 'Oculis (Switzerland) ', 'REGENXBIO Inc. (USA) ', 'Adverum Biotechnologies, Inc. (USA) ', 'Kodiak Sciences Inc. (USA) ', 'EyePoint Pharmaceuticals, Inc. (USA) ', 'Apellis Pharmaceuticals, Inc. (USA) ', 'Iveric Bio, Inc. (USA) (Acquired by Astellas) ', 'Annexon Biosciences (USA) ', 'Hemera Biosciences (USA) (Acquired by Roche) ', 'Gyroscope Therapeutics (UK) (Acquired by Novartis) ', 'Graybug Vision, Inc. (USA) ', 'Clearside Biomedical, Inc. (USA) ', 'Ocuphire Pharma, Inc. (USA) ', 'Lineage Cell Therapeutics, Inc. (USA) ', 'Ocugen, Inc. (USA)'

Increased Prevalence of Disorders Related to the EyesThe prevalence of eye-related illnesses is rising, particularly in developed countries, which will drive the global market for retinal medications over the forecast period. According to an update from the American Academy of Ophthalmology, approximately 93 million people worldwide had diabetic retinopathy in 2016, with 4.2 million of those patients being Americans. According to the NCBI, by 2040, there will be 14.9 to 21.5 million people with early AMD and 3.9 to 4.8 million people with late AMD in Europe. Increasing health education activities regarding eye disorders to seek early treatment and prevent vision impairment in developing regions are also expected to fuel the global retinal disease therapeutics market growth during the forecast period.

Emergence of High-End Technologies to Support Market Development: Retinal gene therapy is typically used to treat inherited retinal disorders. Through RPE65 gene mutation, gene therapy can improve vision impairment. Patients with type 2 Leber's congenital amaurosis are treated with Luxturna, a recently developed gene therapy. This condition is a hereditary disease that impairs vision at birth and creates a degeneration that is quite progressive. Many retinal gene therapies are currently in the clinical trial stage and involve recombinant viruses. Over the evaluation period, from 2022 to 2028, this factor is projected to boost the global retinal disease therapeutics market.

North America is expected to lead the global market for treating retinal illnesses, due to a higher rate of treatment seeking and higher uptake of retinal disease treatment choices. Owing to substantially higher prevalence of retinal illnesses and higher rate of treatment seeking, Europe is expected to be the second most attractive market for the treatment of retinal disorders. Due to rapidly rising disease awareness and increased product penetration, Asia-Pacific is expected to have the fastest growth in the global market for treating retinal diseases. India and China, two of the world's fastest-growing economies, are also projected to contribute to the market growth for treating retinal diseases in the APAC region. Latin America’s market is expected to witness steady growth due to increased diagnosis of the condition. Due to low rates of treatment seeking, limited product penetration, and low rates of diagnosis, the Middle East and Africa have the least market share in the global market.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

Click here right-arrow
logo-images

Related Reports

Retinal Disorder Treatment Market
Buy Now GET FREE SAMPLE
Ophthalmic Disease Therapeutics Market
Buy Now GET FREE SAMPLE
Macular Degeneration Treatment Market
Buy Now GET FREE SAMPLE
Artificial Retina Market
Buy Now GET FREE SAMPLE
Diabetic Retinopathy Market
Buy Now GET FREE SAMPLE
Retinal Vein Occlusion Treatment Market
Buy Now GET FREE SAMPLE
Ophthalmic Drugs Market
Buy Now GET FREE SAMPLE
Eye Health Supplements Market
Buy Now GET FREE SAMPLE

Feedback From Our Clients

Global retinal disease therapeutics market
Retinal Disease Therapeutics Market

Report ID: SQMIG35H2062

[email protected]
USA +1 351-333-4748

BUY NOW GET FREE SAMPLE